Patrícia Silva, PhD, director of science content —

Boehringer Ingelheim Pharmaceuticals, Inc., recently announced data on the first 49 patients participating in the IPF-PRO (Idiopathic Pulmonary Fibrosis – PROspective Outcomes) Registry, better characterizing the features of patients with IPF when they are diagnosed with the disease. The data was presented at the American College of…

The program for the upcoming PFF Summit 2015: From Bench to Bedside has been announced by the Pulmonary Fibrosis Foundation (PFF), the organizer of the event. The third biennial international healthcare conference on pulmonary fibrosis (PF) will take place between November 12 and 14 in Washington, D.C., and will…

ProMetic Life Sciences, Inc., a biopharmaceutical company focused on plasma-derived therapeutics and small-molecule drug development, recently announced that its product PBI-4050 for the treatment of idiopathic pulmonary fibrosis (IPF) has been granted orphan drug designation status by the European Commission. IPF is a progressive fatal lung disease of unknown…

A new study published in the journal Respiratory Research revealed that an enzyme called matrix metalloproteinase 10 may be a suitable novel biomarker for idiopathic pulmonary fibrosis (IPF). The study was led by researchers at the Kyoto University in Japan and is entitled “Matrix metalloproteinase-10:…

Sixty-six year old Dan Castner was living life to the fullest when he started experiencing difficulties in breathing. While he worked in the outdoor industry for more than 40 years and was used to biking, climbing, camping, skiing and hiking, in March of 2012 his life completely changed. Castner was diagnosed with…

A new study recently published in the journal Respiratory Research revealed that a uridine-based therapy can improve pulmonary fibrosis symptoms in a mouse model. The study is entitled “Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis,” and was…

Researchers at Robley Rex VA Medical Center and the University of Louisville recently published in the journal Scientific Reports the finding that the vagus nerve can modulate pulmonary fibrosis pathogenesis in mice. The study is entitled “Vagotomy attenuates bleomycin-induced pulmonary fibrosis in…

Moerae Matrix Inc. recently announced the start of a second Phase 1 clinical trial with MMI-0100, a therapeutic drug developed for pulmonary disorders associated with fibrosis and inflammation, as is the case with idiopathic pulmonary fibrosis (IPF). IPF is a progressive fatal lung disease in which the alveoli and the…

A new study led by researchers at the Comprehensive Pneumology Center (CPC) at Helmholtz Zentrum Munich in Germany recently revealed a new mechanism that contributes to the development of idiopathic pulmonary fibrosis (IPF). The study is entitled “Regulation of 26S Proteasome Activity in Pulmonary Fibrosis” and…

A new study recently published in the journal Respirology reviewed the growing evidence of a link between cigarette smoking and the development of interstitial lung diseases (ILD) including idiopathic pulmonary fibrosis (IPF). The study is entitled “Smoking-related idiopathic interstitial pneumonia: A review” and was developed…